FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

Regeneron Pharma (REGN) PT Raised to $315 at Barclays

November 7, 2018 7:34 AM EST

Barclays analyst Geoff Meacham raised the price target on Regeneron Pharma (NASDAQ: REGN) to $315.00 (from $305.00) while maintaining a Underweight rating following the company's 3Q earnings report.

Meacham thought Regenerons 3Q results were very good (+$22M top-line; +$0.70 bottom-line), and while Barclays continues to... More